Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-300 in Major Depressive Disorder
NCT05157945Phase 2Completed
- Sponsor
- Alto Neuroscience
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of agomelatine in major depressive disorder (MDD), sponsored by Alto Neuroscience. Started Feb 2022; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05157945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157945.